Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) have received an average rating of “Moderate Buy” from the fourteen ratings firms that are currently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year price […]
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) saw a significant drop in short interest in March. As of March 31st, there was short interest totalling 4,960,000 shares, a drop of 9.8% from the March 15th total of 5,500,000 shares. Approximately 4.8% of the shares of the stock are sold short. Based on an average daily […]
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) was the target of a significant decline in short interest in March. As of March 31st, there was short interest totalling 4,960,000 shares, a decline of 9.8% from the March 15th total of 5,500,000 shares. Based on an average daily trading volume, of 1,100,000 shares, the days-to-cover ratio […]
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) gapped up before the market opened on Wednesday . The stock had previously closed at $26.23, but opened at $27.81. Arrowhead Pharmaceuticals shares last traded at $29.58, with a volume of 470,763 shares changing hands. Analysts Set New Price Targets A number of equities research analysts have weighed […]
Sanford C. Bernstein initiated coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) in a research note issued to investors on Tuesday, The Fly reports. The brokerage issued a market perform rating and a $27.00 price target on the biotechnology company’s stock. A number of other research analysts have also recently issued reports on […]